Acusphere ACUS · USD

Its shares trade under the ticker ACUS. It has been listed since 8 October 2003. In the fiscal year to 31 December 2008, it reported revenue of $2.7m and a net loss of $67.7m. At that date it held total assets of $23.1m and shareholders' equity of −$28.5m.

Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Martyn GreenacreChairman of the Board, since 2001
• Mr. Mark LeuchtenbergerPresident, Chief Executive Officer, Director, since 2013
• Ms. Sherri ObergVice Chairman of the Board, since 1993$612,653
• Dr. William RamageChief Development Officer
• Mr. Garen BohlinDirector
• Ms. Sandra FenwickDirector
• Mr. Derek Lemke-von AmmonDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.